Essex Financial Services Inc. Purchases 676 Shares of Eli Lilly And Co (LLY)

Essex Financial Services Inc. increased its position in Eli Lilly And Co (NYSE:LLY) by 1.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,472 shares of the company’s stock after buying an additional 676 shares during the quarter. Eli Lilly And Co accounts for 0.9% of Essex Financial Services Inc.’s portfolio, making the stock its 28th largest position. Essex Financial Services Inc.’s holdings in Eli Lilly And Co were worth $4,021,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its position in Eli Lilly And Co by 8.3% in the first quarter. Principal Financial Group Inc. now owns 1,807,947 shares of the company’s stock valued at $139,881,000 after purchasing an additional 138,746 shares during the last quarter. Trust Co. of Vermont lifted its position in Eli Lilly And Co by 10.1% in the second quarter. Trust Co. of Vermont now owns 9,708 shares of the company’s stock valued at $828,000 after purchasing an additional 893 shares during the last quarter. Xact Kapitalforvaltning AB lifted its position in Eli Lilly And Co by 3.9% in the second quarter. Xact Kapitalforvaltning AB now owns 205,241 shares of the company’s stock valued at $17,513,000 after purchasing an additional 7,697 shares during the last quarter. First Citizens Bank & Trust Co. bought a new stake in Eli Lilly And Co in the second quarter valued at approximately $296,000. Finally, Pennsylvania Trust Co lifted its position in Eli Lilly And Co by 9.2% in the second quarter. Pennsylvania Trust Co now owns 12,995 shares of the company’s stock valued at $1,109,000 after purchasing an additional 1,100 shares during the last quarter. Institutional investors own 76.17% of the company’s stock.

Several analysts have weighed in on the company. Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a research report on Tuesday, July 24th. Societe Generale set a $106.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a research report on Wednesday. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group set a $84.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a research report on Friday, July 13th. Finally, TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b+” rating in a research report on Tuesday. Nine analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus price target of $111.19.

In related news, SVP Alfonso G. Zulueta sold 6,000 shares of the company’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total value of $637,860.00. Following the sale, the senior vice president now directly owns 55,224 shares of the company’s stock, valued at $5,870,863.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 14,632 shares of the company’s stock in a transaction on Monday, October 8th. The stock was sold at an average price of $115.91, for a total value of $1,695,995.12. Following the completion of the sale, the insider now directly owns 119,191,172 shares in the company, valued at $13,815,448,746.52. The disclosure for this sale can be found here. Insiders have sold 1,881,684 shares of company stock worth $133,274,076 over the last three months. Insiders own 0.11% of the company’s stock.

LLY opened at $112.21 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.09 and a current ratio of 1.91. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $116.61. The company has a market cap of $116.23 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 1.75 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The firm had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period in the previous year, the firm earned $1.05 earnings per share. The business’s revenue was up 7.1% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly And Co will post 5.57 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be paid a dividend of $0.5625 per share. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.01%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

TRADEMARK VIOLATION NOTICE: “Essex Financial Services Inc. Purchases 676 Shares of Eli Lilly And Co (LLY)” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://transcriptdaily.com/2018/11/10/essex-financial-services-inc-purchases-676-shares-of-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply